Kymera Therapeutics
KYMRKymera Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to treat diseases with known biology that have been historically difficult to drug.
Earnings
Next report
Aug 10, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to treat diseases with known biology that have been historically difficult to drug. The company leverages its proprietary Pegasus platform to discover and develop oral small molecule medicines that selectively eliminate disease-causing proteins by engaging the body's natural cellular recycling system. Their primary focus is on high-value targets in immunology and oncology to address significant unmet medical needs.
A leader in targeted protein degradation with a proprietary platform and multiple programs in clinical development.
Questions, answered.
- What is Kymera Therapeutics's market cap?
- Kymera Therapeutics (KYMR) has a market capitalization of $9.1B and trades on NASDAQ.
- What is Kymera Therapeutics's revenue and profitability?
- Kymera Therapeutics generated $51.5M in trailing twelve-month revenue with a net loss of $315.0M, representing a net margin of -612.0%, with free cash flow of -$244.0M. These figures are based on the Q1 2026 filing.
- Who are Kymera Therapeutics's competitors?
- Kymera Therapeutics's key competitors include Regeneron Pharmaceuticals, Inc., C4 Therapeutics, Inc., Arvinas, Inc., and others. These companies compete in similar markets and product categories.
- Who does Kymera Therapeutics partner with?
- Kymera Therapeutics's notable partners include Sanofi, Gilead Sciences.
- Where is Kymera Therapeutics headquartered?
- Kymera Therapeutics is headquartered in United States of America and employs approximately 186 people. It has been publicly traded since 2020.
